Barclays Maintains an 'Equalweight' on Genzyme (GENZ); Slightly Weaker Results, Focus Remains on Sanofi Process
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on Genzyme (NASDAQ: GENZ), PT $75.
Barclays analyst says, "GENZ CEO Henri Termeer provided a corporate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "GENZ CEO Henri Termeer provided a corporate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
